19Jun 2022
Bromocriptine Quick‐Release as Adjunct Therapy in Youth and Adults with Type 1 Diabetes: A Randomized, Placebo‐Controlled Crossover Study

Bromocriptine Quick‐Release as Adjunct Therapy in Youth and Adults with Type 1 Diabetes: A Randomized, Placebo‐Controlled Crossover Study

To evaluate the potential for glycemic, renal, and vascular benefits of Bromocriptine Quick Release (BCQR) in youth and adults with type 1 diabetes. Greater hyperglycemia, insulin resistance, metabolic dysfunction and renal hyperfiltration in adolescents argues for increased attention during this high‐risk age period. Though BCQR had little impact on glycemia or insulin sensitivity, initial vascular and renal responses suggest potential benefits of BCQR in youth and adults with type 1 diabetes requiring further study.

  • #endo-diabetology

Like

Save

Share